IP Group PLC Inivata receives $25m investment from NeoGenomics
May 26 2020 - 4:05AM
RNS Non-Regulatory
TIDMIPO
IP Group PLC
26 May 2020
FOR RELEASE ON 26 May 2020
Portfolio company Inivata announces strategic collaboration and
$25m investment from NeoGenomics
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the
developer of intellectual property-based businesses, is pleased to
note that portfolio company Inivata Ltd, ("Inivata" or "the
Company"), a leader in liquid biopsy, has announced the formation
of a strategic collaboration with NeoGenomics, Inc (NASDAQ: NEO)
for the commercialisation of its InVisionFirst(R)-Lung liquid
biopsy test in the United States.
As part of the collaboration, NeoGenomics will make a $25
million equity investment in Inivata to take a minority
shareholding with an option to buy the company outright. The new
funding received by Inivata will be used to enable the acceleration
of its liquid biopsy products, including further development work
on RaD aR, its newly launched highly sensitive personalised assay
for the detection of residual disease and recurrence.
Following completion of the initial equity investment, IP Group
will hold a direct undiluted beneficial stake of 25.7% in Inivata.
The directors expect that this transaction will result in a direct
unrealised fair value gain to the Group of approximately GBP7.0
million and that the Group's holding will be valued at
approximately GBP31.0 million.
NeoGenomics and Inivata will also seek opportunities for
collaboration with biopharmaceutical companies around Inivata's
liquid biopsy platform drawing on both companies' technology and
expertise.
For more information, please contact:
IP Group plc www.ipgroupplc.com
+44 (0) 20 7444 0050
Alan Aubrey, Chief Executive Officer
Greg Smith, Chief Financial Officer +44 (0) 20 7444 0062/+44 (0)
Liz Vaughan-Adams, Communications 7979 853802
Charlotte Street Partners
Andrew Wilson +44 (0) 7810 636995
David Gaffney +44 (0) 7854 609998
Notes for editors
About IP Group
IP Group is a leading intellectual property commercialisation
company which focuses on evolving great ideas, mainly from its
partner universities, into world-changing businesses. The Group has
pioneered a unique approach to developing these ideas and the
resulting businesses by providing access to business building
expertise, capital (through its 100%-owned FCA-authorised
subsidiaries IP Capital and Parkwalk Advisors), networks,
recruitment and business support. IP Group has a strong track
record of success and its portfolio comprises holdings in early
stage to mature businesses across life sciences and technology. IP
Group is listed on the Main Market of the London Stock Exchange
under the code IPO.
Group holdings in portfolio companies reflect the undiluted
beneficial equity interest excluding debt, unless otherwise
explicitly stated.
For more information, please visit our website at
www.ipgroupplc.com .
ENDS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUVSRRRVUVUUR
(END) Dow Jones Newswires
May 26, 2020 05:05 ET (09:05 GMT)
Ip (LSE:IPO)
Historical Stock Chart
From Apr 2024 to May 2024
Ip (LSE:IPO)
Historical Stock Chart
From May 2023 to May 2024